The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).
 
Brodie Miles
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Daqin Mao
No Relationships to Disclose
 
Saran Vardhanabhuti
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
Research Funding - Kite, a Gilead Company
 
Christina Ann To
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Marco Andreas Schupp
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Shilpa Shahani
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Hairong Xu
Employment - Kite, a Gilead Company
 
Javier Munoz
Honoraria - Curio Science; Kyowa Hakko Kirin; OncView; Physicans' Education Resource; Seagen; Targeted Oncology
Consulting or Advisory Role - ADC Therapeutics; Alexion Pharmaceuticals; Aurobindo; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Fosun Kite; Genentech; Genmab; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Seagen; Secura Bio; SERVIER; TG Therapeutics; Zodiac Pharma
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Jason Westin
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Genentech/Roche; Iksuda Therapeutics; Janssen Scientific Affairs; Kite/Gilead; Merck; Monte Rosa Therapeutics; MorphoSys/Incyte; Novartis; Seagen
Research Funding - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis
 
Rhine Shen
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite/Gilead
Patents, Royalties, Other Intellectual Property - Atara Biotherapeutics
 
Simone Filosto
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Kite, a Gilead Company
Patents, Royalties, Other Intellectual Property - Tusk Therapeutics